Drugs make headway against lung, breast, prostate cancers
Companies, agencies, institutions, etc
AP
Merck
Keytruda
the American Society of Clinical Oncology
the New England Journal of Medicine
Vanderbilt-Ingram Cancer Center
Novartis
Pfizer
Astellas Pharma Inc.
the University of North Carolina’s
Lineberger Comprehensive Cancer Center
Marchione
http://twitter.com/MMarchioneAPThe Associated Press Health and Science Department
the Howard Hughes Medical Institute’s Department of Science Education
People
Roszell Mack Jr.
Leora Horn
Kisqali
Zytiga
Janssen
Ethan Basch
Erleada
Groups
Herceptin
Physical locations
No matching tags
Places
No matching tags
Locations
CHICAGO
Lexington
Kentucky
Chicago
Nashville
Tennessee
U.S.
Zytiga
Xtandi
Events
No matching tags
Summary
After two years, survival was 82% among those on Erleada and 74% among those who weren’t.Men now have a choice of four drugs that give similar benefits, and no studies yet have compared them against each other, said Dr. Ethan Basch, a prostate specialist at the University of North Carolina’s Lineberger Comprehensive Cancer Center who has no financial ties to any drugmakers.Cost and side effects may help patients decide, he said.
As said here by MARILYNN MARCHIONE